Submit the form below to receive email alerts when Intellicure publishes a new blog post! This information will not be shared.
You May Also Like …
A landmark systematic review has been completed which concludes that that HBOT may be one of the most important tools we have for tissue ischemia patients.
Blue Cross and Blue Shield of Texas will “enhance” its claims editing and review process for office, inpatient, and outpatient evaluation and management (E/M) services for patients in commercial plans.
Physicians who submitted 2024 performance data in MIPS can preview that information through Thursday, June 11, at 8 pm ET on the QPP website.